Integra LifeSciences Holdings Corporation (Nasdaq: IART) lowered its full-year 2026 revenue and earnings guidance after flooding at its Cincinnati manufacturing facility disrupted production during the third quarter.

The company now expects full-year 2026 revenue of $1.634 billion to $1.654 billion, down from its prior outlook of $1.654 billion to $1.695 billion. Adjusted earnings per diluted share guidance was reduced to a range of $2.30 to $2.40, from a prior range of $2.40 to $2.50. The company maintained its operating cash flow forecast at approximately $190 million to $200 million for the full year.

For the third quarter of 2026, Integra expects to report revenue of approximately $410 million to $412 million and adjusted earnings per diluted share of $0.55 to $0.59. These figures are preliminary and unaudited.

The July 2026 flooding at the Cincinnati facility damaged portions of the building, equipment, inventory, and other assets. The facility manufactures products within the company's Specialty Surgical Technologies portfolio. Integra estimates the supply disruption reduced third quarter revenue by approximately $7 million and expects an additional $15 million to $20 million negative impact on fourth quarter revenue. The company does not expect a return to full manufacturing operations at the site until the second quarter of 2027.

Integra said it holds property and business interruption insurance covering the Cincinnati facility and expects insurance recoveries to offset a substantial portion of the earnings impact during the recovery period. The company said it continues to work with its insurance carrier to assess recoverable losses.

Stuart Essig, Chairman and Chief Executive Officer, said the company expects "strong cash generation" and noted progress in "improving product availability, the return of key products to market, and strengthening commercial execution."

Integra said it will report full third quarter 2026 financial results during a conference call in October 2026.